Next Article in Journal
Potential Use of Common Administration of Emulsion for Parenteral Nutrition and Vinpocetine: Compatibility Study and Prospect
Previous Article in Journal
Branched-Chain Amino Acids, Alanine, and Thyroid Function: A Cross-Sectional, Nuclear Magnetic Resonance (NMR)-Based Approach from ELSA-Brasil
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment

Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 17138, Jordan
*
Author to whom correspondence should be addressed.
Metabolites 2024, 14(8), 438; https://doi.org/10.3390/metabo14080438
Submission received: 14 July 2024 / Revised: 2 August 2024 / Accepted: 5 August 2024 / Published: 6 August 2024

Abstract

Hyperlipidemia is a lipid metabolism disorder that refers to increased levels of total triglycerides (TGs), cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) and decreased levels of high-density lipoprotein-cholesterol (HDL-C). It is a major public health issue with increased prevalence and incidence worldwide. The ability to identify individuals at risk of this disorder before symptoms manifest will facilitate timely intervention and management to avert potential complications. This can be achieved by employing metabolomics as an early detection method for the diagnostic biomarkers of hyperlipidemia. Metabolomics is an analytical approach used to detect and quantify metabolites. This provides the ability to explain the metabolic processes involved in the development and progression of certain diseases. In recent years, interest in the use of metabolomics to identify disease biomarkers has increased, and several biomarkers have been discovered, such as docosahexaenoic acid, glycocholic acid, citric acid, betaine, and carnitine. This review discusses the primary metabolic alterations in the context of hyperlipidemia. Furthermore, we provide an overview of recent studies on the application of metabolomics to the assessment of the efficacy of traditional herbal products and common lipid-lowering medications.
Keywords: biomarkers; hyperlipidemia; metabolic pathway; metabolites; metabolomics biomarkers; hyperlipidemia; metabolic pathway; metabolites; metabolomics

Share and Cite

MDPI and ACS Style

Alwahsh, M.; Alejel, R.; Hasan, A.; Abuzaid, H.; Al-Qirim, T. The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment. Metabolites 2024, 14, 438. https://doi.org/10.3390/metabo14080438

AMA Style

Alwahsh M, Alejel R, Hasan A, Abuzaid H, Al-Qirim T. The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment. Metabolites. 2024; 14(8):438. https://doi.org/10.3390/metabo14080438

Chicago/Turabian Style

Alwahsh, Mohammad, Rahaf Alejel, Aya Hasan, Haneen Abuzaid, and Tariq Al-Qirim. 2024. "The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment" Metabolites 14, no. 8: 438. https://doi.org/10.3390/metabo14080438

APA Style

Alwahsh, M., Alejel, R., Hasan, A., Abuzaid, H., & Al-Qirim, T. (2024). The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment. Metabolites, 14(8), 438. https://doi.org/10.3390/metabo14080438

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop